152 related articles for article (PubMed ID: 37366362)
1. Role of Alpha-7-Nicotinic Acetylcholine Receptor in Alzheimer's Disease.
Singh S; Agrawal N; Goyal A
CNS Neurol Disord Drug Targets; 2024; 23(3):384-394. PubMed ID: 37366362
[TBL] [Abstract][Full Text] [Related]
2. Alpha 7 nicotinic acetylcholine receptor and its effects on Alzheimer's disease.
Ma KG; Qian YH
Neuropeptides; 2019 Feb; 73():96-106. PubMed ID: 30579679
[TBL] [Abstract][Full Text] [Related]
3. beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology.
Wang HY; Lee DH; D'Andrea MR; Peterson PA; Shank RP; Reitz AB
J Biol Chem; 2000 Feb; 275(8):5626-32. PubMed ID: 10681545
[TBL] [Abstract][Full Text] [Related]
4. Increased Aβ
Wang HY; Trocmé-Thibierge C; Stucky A; Shah SM; Kvasic J; Khan A; Morain P; Guignot I; Bouguen E; Deschet K; Pueyo M; Mocaer E; Ousset PJ; Vellas B; Kiyasova V
Alzheimers Res Ther; 2017 Jul; 9(1):54. PubMed ID: 28750690
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic Cholinergic Mechanisms in Alzheimer's Disease.
Shen J; Wu J
Int Rev Neurobiol; 2015; 124():275-92. PubMed ID: 26472533
[TBL] [Abstract][Full Text] [Related]
6. Selective coactivation of α7- and α4β2-nicotinic acetylcholine receptors reverses beta-amyloid-induced synaptic dysfunction.
Roberts JP; Stokoe SA; Sathler MF; Nichols RA; Kim S
J Biol Chem; 2021; 296():100402. PubMed ID: 33571523
[TBL] [Abstract][Full Text] [Related]
7. The p38 mitogen activated protein kinase regulates β-amyloid protein internalization through the α7 nicotinic acetylcholine receptor in mouse brain.
Ma KG; Lv J; Yang WN; Chang KW; Hu XD; Shi LL; Zhai WY; Zong HF; Qian YH
Brain Res Bull; 2018 Mar; 137():41-52. PubMed ID: 29128415
[TBL] [Abstract][Full Text] [Related]
8. Targeting the alpha 7 nicotinic acetylcholine receptor to reduce amyloid accumulation in Alzheimer's disease pyramidal neurons.
D'Andrea MR; Nagele RG
Curr Pharm Des; 2006; 12(6):677-84. PubMed ID: 16472157
[TBL] [Abstract][Full Text] [Related]
9. Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development.
Burns LH; Pei Z; Wang HY
Drug Dev Res; 2023 Sep; 84(6):1085-1095. PubMed ID: 37291958
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the MAPKs pathways affects Aβ-induced cognitive deficits in Alzheimer's disease via activation of α7nAChR.
Chang KW; Zong HF; Rizvi MY; Ma KG; Zhai W; Wang M; Yang WN; Ji SF; Qian YH
Neurobiol Learn Mem; 2020 Feb; 168():107154. PubMed ID: 31904546
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease.
Dziewczapolski G; Glogowski CM; Masliah E; Heinemann SF
J Neurosci; 2009 Jul; 29(27):8805-15. PubMed ID: 19587288
[TBL] [Abstract][Full Text] [Related]
12. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
[TBL] [Abstract][Full Text] [Related]
13. Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.
Ikonomovic MD; Wecker L; Abrahamson EE; Wuu J; Counts SE; Ginsberg SD; Mufson EJ; Dekosky ST
Arch Neurol; 2009 May; 66(5):646-51. PubMed ID: 19433665
[TBL] [Abstract][Full Text] [Related]
14. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain.
Wang HY; Stucky A; Liu J; Shen C; Trocme-Thibierge C; Morain P
J Neurosci; 2009 Sep; 29(35):10961-73. PubMed ID: 19726654
[TBL] [Abstract][Full Text] [Related]
15. Modified Snake α-Neurotoxin Averts β-Amyloid Binding to α7 Nicotinic Acetylcholine Receptor and Reverses Cognitive Deficits in Alzheimer's Disease Mice.
Fonar G; Polis B; Sams DS; Levi A; Malka A; Bal N; Maltsev A; Elliott E; Samson AO
Mol Neurobiol; 2021 May; 58(5):2322-2341. PubMed ID: 33417228
[TBL] [Abstract][Full Text] [Related]
16. Expression levels of the α7 nicotinic acetylcholine receptor in the brains of patients with Alzheimer's disease and their effect on synaptic proteins in SH-SY5Y cells.
Ren JM; Zhang SL; Wang XL; Guan ZZ; Qi XL
Mol Med Rep; 2020 Sep; 22(3):2063-2075. PubMed ID: 32582986
[TBL] [Abstract][Full Text] [Related]
17. Modulation of α7 nicotinic acetylcholine receptor and fibrillar amyloid-β interactions in Alzheimer's disease brain.
Ni R; Marutle A; Nordberg A
J Alzheimers Dis; 2013; 33(3):841-51. PubMed ID: 23042213
[TBL] [Abstract][Full Text] [Related]
18. Loss of alpha7 nicotinic receptors enhances beta-amyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease.
Hernandez CM; Kayed R; Zheng H; Sweatt JD; Dineley KT
J Neurosci; 2010 Feb; 30(7):2442-53. PubMed ID: 20164328
[TBL] [Abstract][Full Text] [Related]
19. α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both?
Hernandez CM; Dineley KT
Curr Drug Targets; 2012 May; 13(5):613-22. PubMed ID: 22300028
[TBL] [Abstract][Full Text] [Related]
20. Beyond acetylcholinesterase inhibitors for treating Alzheimer's disease: α7-nAChR agonists in human clinical trials.
Russo P; Del Bufalo A; Frustaci A; Fini M; Cesario A
Curr Pharm Des; 2014; 20(38):6014-21. PubMed ID: 24641224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
